natgillin/translations-raw huggingface dataset:
Hyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. 
Zdravilo Hyrimoz je indicirano za zdravljenje aktivnega in napredujočega psoriatičnega artritisa pri odraslih, če odziv na predhodno zdravljenje z imunomodulirajočimi antirevmatiki ni bil ustrezen.
• Do not give Hyrimoz to children with paediatric Crohn's disease below the age of 6 years. 
• Zdravila Hyrimoz ne smete dati otroku s Crohnovo boleznijo, če je star manj kot 6 let.
Thus, it is not possible to use Hyrimoz for children who require less than a full 40 mg dose. 
Zato zdravila Hyrimoz ni mogoče uporabljati pri otroci, ki potrebujejo manj kot polni odmerek 40 mg.
Figure A: Hyrimoz pre-filled syringe with needle guard and add-on finger flange 
Slika A: Napolnjena injekcijska brizga zdravila Hyrimoz s ščitnikom za iglo in držalom
The Hyrimoz 40 mg pre-filled syringe should not be used in children or adolescents weighing less than 40 kg with Crohn's disease, since it is not possible to administer doses less than 40 mg. 
Zdravila Hyrimoz 40 mg napolnjena injekcijska brizga ne smete uporabljati pri otrocih ali mladostnikih s Crohnovo boleznijo, ki tehtajo manj kot 40 kg, saj ni mogoče dati odmerka, manjšega od 40 mg.
Hyrimoz is intended for the treatment of the following inflammatory diseases: 
Zdravilo Hyrimoz je namenjeno za zdravljenje vnetnih bolezni, opisanih spodaj:
Children and adolescents from 4 to 17 years of age weighing 30 kg or more The recommended dose of Hyrimoz is an initial dose of 40 mg, followed by 40 mg one week later. 
Otroci in mladostniki, stari od 4 do 17 let, ki tehtajo 30 kg ali več Priporočeni odmerek zdravila Hyrimoz je začetni odmerek 40 mg, ki mu sledi 40 mg en teden kasneje.
Hyrimoz works by reducing this inflammation. 
Zdravilo Hyrimoz deluje tako, da zmanjša tako vnetje.
Hyrimoz dose for paediatric patients with Crohn's disease 
Odmerjanje zdravila Hyrimoz pri pediatričnih bolnikih s Crohnovo boleznijo
• You should consider the use of adequate contraception to prevent pregnancy and continue its use for at least 5 months after the last Hyrimoz treatment. 
Nosečnost in dojenje • Premisliti morate o uporabi ustrezne kontracepcijske zaščite za preprečitev nosečnosti in z njo nadaljevati vsaj še 5 mesecev po zadnjem zdravljenju z zdravilom Hyrimoz.
• Do not give Hyrimoz to children with polyarticular juvenile idiopathic arthritis below the age of 
• Zdravila Hyrimoz ne smete dati otroku s poliartikularnim juvenilnim idiopatskim artritisom, če je star manj kot 2 leti.
If these medicines do not work well enough, patients will be given Hyrimoz to treat their polyarticular juvenile idiopathic arthritis or enthesitis-related arthritis. 
Če ta zdravila ne delujejo dovolj dobro, bolniki za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa ali artritisa, povezanega z entezitisom, dobijo zdravilo Hyrimoz.
* Note: Hyrimoz is currently only available as 40 mg pre-filled syringe and 40 mg pre-filled pen. 
* Opomba: Zdravilo Hyrimoz je trenutno na voljo samo v 40 mg napolnjeni injekcijski brizgi in 40 mg napolnjenem injekcijskem peresniku.
For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, dyspnoea, and / or pulmonary infiltrates or other serious systemic illness with or without concomitant shock an invasive fungal infection should be suspected and administration of Hyrimoz should be promptly discontinued. 
Če se bolniku pojavijo znaki ali simptomi, kot so npr. zvišana telesna temperatura, splošno slabo počutje, hujšanje, znojenje, kašelj, dispneja in/ali pljučni infiltrati ali druga sistemska bolezen (s spremljajočim šokom ali brez njega), je treba posumiti na invazivno glivično okužbo.
• high blood measurements for white blood cells; 
• visoke krvne vrednosti za bele krvne celice;
Non-serious allergic reactions associated with adalimumab were uncommon during clinical trials. 
Z adalimumabom povezane alergijske reakcije, ki niso bile resne, so se v kliničnih študijah pojavljale občasno.
• For a more comfortable injection, take your pen out of the refrigerator 15 to 30 minutes before injecting Hyrimoz to allow it to reach room temperature. 
• Da bo injiciranje prijetnejše, vzemite injekcijski peresnik iz hladilnika približno od 15 do 30 minut pred injiciranjem zdravila , da se ogreje na sobno temperaturo.
It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating Hyrimoz therapy. 
Za pediatrične bolnike je priporočljivo, da pred začetkom zdravljenja z zdravilom Hyrimoz opravijo vsa cepljenja v skladu z veljavnimi smernicami za cepljenje, če je le mogoče.
When Hyrimoz therapy is initiated, a loading dose of 40 mg for patients < 30 kg or 80 mg for patients ≥ 30 kg may be administered one week prior to the start of maintenance therapy. 
Na začetku zdravljenja z zdravilom Hyrimoz se lahko pri bolnikih < 30 kg uporabi polnilni odmerek 40 mg in pri bolnikih ≥ 30 kg polnilni odmerek 80 mg en teden pred začetkom vzdrževalnegazdravljenja.
If these medicines do not work well enough, you will be given Hyrimoz to reduce the signs and symptoms of your disease. 
Če ta zdravila ne bodo dovolj dobro delovala, boste dobili zdravilo Hyrimoz za zmanjšanje znakov in simptomov vaše bolezni.
Disposing of used syringes” at the end of these Instructions for Use. 
Odstranjevanje uporabljenih injekcijskih brizg” na koncu teh navodil za uporabo.
If you have rheumatoid arthritis and you do not receive methotrexate with your Hyrimoz therapy, your doctor may decide to give 40 mg adalimumab every week or 80 mg every other week. 
Če imate revmatoidni artritis in če hkrati z zdravilom Hyrimoz ne dobivate metotreksata, vam bo zdravnik morda predpisal 40 mg adalimumaba vsak teden ali 80 mg vsak drugi teden.
Hyrimoz dose for patients with polyarticular juvenile idiopathic arthritis 
Odmerjanje zdravila Hyrimoz pri bolnikih s poliartikularnim juvenilnim idiopatskim artritisom
Methotrexate should be continued during treatment with Hyrimoz. 
Med zdravljenjem z zdravilom Hyrimoz je treba še naprej uporabljati metotreksat.
• that Hyrimoz treatment may increase the potential risks of o infections, including tuberculosis o cancer o nervous system problems o vaccinations 
• obvestilo, da lahko zdravljenje z zdravilom Hyrimoz poveča tveganje o okužb, vključno s tuberkulozo; o raka;
The recommended Hyrimoz induction dose regimen for adult patients with moderately to severely active Crohn's disease is 80 mg at week 0 followed by 40 mg at week 2. 
Priporočena shema odmerjanja zdravila Hyrimoz med indukcijo je pri odraslih bolnikih z zmerno do hudo, aktivno Crohnovo boleznijo 80 mg 0. teden in nato 40 mg 2. teden.
If these medicines do not work well enough, you will be given Hyrimoz to treat your rheumatoid arthritis. 
Če ta zdravila ne delujejo dovolj dobro, boste za zdravljenje revmatoidnega artritisa dobili zdravilo Hyrimoz.
• Do not give Hyrimoz to children with paediatric plaque psoriasis or paediatric ulcerative colitis below the age of 4 years. 
• Zdravila Hyrimoz ne smete dati otroku z luskavico v plakih ali ulceroznim kolitisom, če je star manj kot 4 leta.
It is recommended that the patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with Hyrimoz. 
Priporočljivo je, da med zdravljenjem z zdravilom Hyrimoz bolnik vsak dan uporablja topikalno antiseptično čistilno sredstvo za čiščenje lezij HS.
Ophthalmologists are advised to consult with an appropriate specialist before initiation of treatment with Hyrimoz (see section 4.4). 
Oftalmologom se svetuje, da se pred začetkom zdravljenja z zdravilom Hyrimoz posvetujejo z ustreznim specialistom
The recommended dose of Hyrimoz for patients with Crohn's disease from 6 to 17 years of age is based on body weight (table 4). 
Priporočeni odmerek zdravila Hyrimoz pri bolnikih s Crohnovo boleznijo, starih od 6 do 17 let, temelji na telesni masi (preglednica 4).
Hyrimoz can slow down the damage to the cartilage and bone of the joints caused by the disease and improve physical function. 
Zdravilo Hyrimoz lahko upočasni okvaro sklepnega hrustanca in kosti, ki jo povzroča ta bolezen, in izboljšuje telesno delovanje.
Thus, it is not possible to administer Hyrimoz to paediatric patients that require less than a full 40 mg dose. 
Zato zdravila Hyrimoz ni mogoče dajati pediatričnim bolnikom, ki potrebujejo odmerek, manjši od 40 mg.
Hyrimoz is used in adults to treat these conditions. 
Zdravilo Hyrimoz se uporablja za zdravljenje teh stanj pri odraslih.
The recommended dose of Hyrimoz for adult patients with rheumatoid arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection. 
Priporočeni odmerek zdravila Hyrimoz za odrasle bolnike z revmatoidnim artritisom je 40 mg adalimumaba vsak drugi teden v enkratnem odmerku v subkutani injekciji.
Hyrimoz is administered every other week via subcutaneous injection. 
Zdravilo Hyrimoz se odmerja vsak drugi teden v obliki subkutane injekcije.
Cartons contain 1 and 2 pre-filled syringes of Hyrimoz. 
Škatle vsebujejo 1 in 2 napolnjeni injekcijski brizgi zdravila Hyrimoz.
Children, adolescents and adults with polyarticular juvenile idiopathic arthritis Children, adolescents and adults from 2 years of age weighing 30 kg or more The recommended dose of Hyrimoz is 40 mg every other week. 
Otroci, mladostniki in odrasli s poliartikularnim juvenilnim idiopatskim artritisom Otroci, mladostniki in odrasli, starejši od 2 let, ki tehtajo 30 kg ali več Priporočeni odmerek zdravila Hyrimoz je 40 mg vsak drugi teden.
• It is important that you tell your baby's doctors and other health care professionals about your Hyrimoz use during your pregnancy before the baby receives any vaccine (for more information on vaccines see the “Warnings and precautions” section). 
• Pomembno je, da obvestite zdravnika vašega dojenčka in druge zdravstvene delavce, da ste med nosečnostjo prejemali zdravilo Hyrimoz, preden bo vaš dojenček prejel katerokoli cepivo.
The recommended dose of Hyrimoz for patients with ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and for patients with psoriatic arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection. 
Priporočeni odmerek zdravila Hyrimoz pri bolnikih z ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za AS in pri bolnikih s psoriatičnim artritisom je 40 mg adalimumaba, apliciran v enkratni subkutani injekciji vsak drugi teden.
Hyrimoz 40 mg solution for injection in a single-use pre-filled syringe Hyrimoz is supplied in a single-use clear type I glass syringe with a rubber stopper and a stainless steel needle with an automatic needle guard with finger flange, rubber needle cap and plastic plunger, containing 0.8 ml solution. 
Hyrimoz 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi za enkratno uporabo Zdravilo Hyrimoz je na voljo v napolnjeni injekcijski brizgi za enkratno uporabo iz prozornega stekla tipa I z gumijasto zaporko in z iglo iz nerjavečega jekla z avtomatskim ščitnikom za iglo z držalom, z gumijastim pokrovčkom za iglo in s plastičnim batom, ki vsebuje 0,8 ml raztopine.
EU/1/18/1286/003 6 pre-filled syringes (3 packs of 2) 
EU/1/18/1286/003 6 napolnjenih injekcijskih brizg (3 pakiranja po 2)
Package leaflet: Information for the patient Hyrimoz 40 mg solution for injection in pre-filled syringe adalimumab This medicine is subject to additional monitoring. 
Navodilo za uporabo Hyrimoz 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku adalimumab Za to zdravilo se izvaja dodatno spremljanje varnosti.
Hyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. 
Zdravilo Hyrimoz je indicirano za zdravljenje zmerno do hudo aktivnega ulceroznega kolitisa pri odraslih bolnikih, ki so se ne odzovejo zadostno na običajno zdravljenje, na primer na kortikosteroide in 6-merkaptopurin (6-MP) ali azatioprin (AZA), ali pa takšnega zdravljenja ne prenesejo oz. imajo zanj medicinske kontraindikacije.
• sensation disorders such as tingling, prickling or numbness; 
• otežkočeno spanje; • motnje v občutenju kot so ščemenje, zbadanje ali omrtvelost;
Hyrimoz is indicated for treatment of moderately to severely active Crohn's disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. 
Zdravilo Hyrimoz je indicirano za zdravljenje zmerno do hudo aktivne Crohnove bolezni pri odraslih bolnikih, ki se ne odzovejo na popoln in ustrezen ciklus zdravljenja s kortikosteroidom in/ali imunosupresivom, ali pa takšnega zdravljenja ne prenesejo oz. imajo zanj medicinske kontraindikacije.
• neurological infections (including viral meningitis); 
• nevrološke okužbe (vključno z virusnim meningitisom); • okužba očesa;
Hyrimoz is used to treat rheumatoid arthritis in adults. 
Zdravilo Hyrimoz se uporablja za zdravljenje revmatoidnega artritisa pri odraslih.
During treatment with Hyrimoz, other concomitant therapies (e.g., corticosteroids and / or immunomodulatory agents) should be optimised. 
Med zdravljenjem z zdravilom Hyrimoz je treba optimizirati druge sočasne terapije (npr.
Children, adolescents and adults with enthesitis-related arthritis Children, adolescents and adults from 6 years of age weighing 30 kg or more The recommended dose of Hyrimoz is 40 mg every other week. 
Otroci, mladostniki in odrasli z artritisom, povezanim z entezitisom Otroci, mladostniki in odrasli, starejši od 6 let, ki tehtajo 30 kg ali več Priporočeni odmerek zdravila Hyrimoz je 40 mg vsak drugi teden.
The recommended Hyrimoz dose for patients with plaque psoriasis from 4 to 17 years of age is based on body weight (table 3). 
Priporočeni odmerek zdravila Hyrimoz pri bolnikih s psoriazo v plakih, starih od 4 do 17 let, temelji na telesni masi (preglednica 3).
If you do not respond well enough to these medicines, you will be given Hyrimoz to reduce the signs and symptoms of your Crohn's disease. 
Če se nanje ne boste odzvali dovolj dobro, boste za zmanjšanje znakov in simptomov Crohnove bolezni dobili zdravilo Hyrimoz.
In these trials, 11.9 % of patients treated with adalimumab and 8.1 % of placebo and active control-treated patients that had negative baseline anti-nuclear antibody titres reported positive titres at week 24. 
prejemnikov adalimumaba in 8,1 % prejemnikov placeba in kontrolne učinkovine, ki so imeli izhodiščno negativne titre teh protiteles.
Hyrimoz is supplied in a single-use pre-filled syringe assembled into a triangular-shaped pen (SensoReady) with transparent window and label. 
Zdravilo Hyrimoz je na voljo v injekcijski brizgi za enkratno uporabo, v injekcijskem peresniku trikotne oblike (SensoReady), s prozornim okencem in oznako.
Hyrimoz is used to treat hidradenitis suppurativa in adults and adolescents from 12 years of age. 
Zdravilo Hyrimoz se uporablja za zdravljenje hidradenitis suppurativa pri odraslih in mladostnikih,
Hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. 
Ankilozirajoči spondilitis (AS) Zdravilo Hyrimoz je indicirano za zdravljenje hudega aktivnega ankilozirajočega spondilitisa pri odraslih, ki se na konvencionalno terapijo ne odzovejo ustrezno.
Serious allergic reactions associated with adalimumab were rare during clinical trials. 
V kliničnih študijah so bile redke resne alergijske reakcije, povezane z adalimumabom.
Patients should be instructed to seek medical advice if signs / symptoms suggestive of a tuberculosis infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after therapy with Hyrimoz. 
Bolnikom je treba naročiti, naj poiščejo zdravniško pomoč, če med zdravljenjem z zdravilom Hyrimoz ali po njem doživijo znake ali simptome, ki nakazujejo tuberkulozno okužbo (npr. trdovraten kašelj, hujšanje/izgubljanje teže, nekoliko zvišano telesno temperaturo).
Hyrimoz is administered by subcutaneous injection. 
Zdravilo Hyrimoz se uporablja kot subkutana injekcija.
Carriers of HBV who require treatment with Hyrimoz should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy. 
Nosilce HBV, ki potrebujejo zdravljenje z zdravilom Hyrimoz, je treba ves čas zdravljenja in več mesecev po koncu zdravljenja natančno spremljati glede znakov in simptomov aktivne okužbe s HBV. O zdravljenju nosilcev HBV s protivirusno terapijo v kombinaciji z antagonistom TNF za preprečitev reaktivacije HBV ni zadostnih podatkov.
It is important to tell your doctor if you get symptoms such as fever, wounds, feeling tired or dental problems. 
Pomembno je, da zdravniku poveste, če doživite simptome, kot so npr. zvišana telesna temperatura, rane, občutek utrujenosti ali težave z zobmi.
Hyrimoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. 
Uveitis pri pediatričnih bolnikih Zdravilo Hyrimoz je indicirano za zdravljenje kroničnega, neinfekcijskega, anteriornega uveitisa pri bolnikih, ki so starejši od 2 let in se niso ustrezno odzvali na konvencionalno zdravljenje, ga ne prenašajo ali pri katerih konvencionalno zdravljenje ni primerno.
Be sure that you read, understand, and follow these Instructions for use before injecting Hyrimoz. 
Preden injicirate zdravilo Hyrimoz, morate ta navodila za uporabo prebrati, razumeti in jih upoštevati.
• inflammation of the eye lid and eye swelling; 
• vnetje očesne veke in otekanje oči;
Hyrimoz dose for patients with enthesitis-related arthritis Patient weight 
Odmerjanje zdravila Hyrimoz pri bolnikih z artritisom, povezanim z entezitisom
EU/1/18/1286/001 1 pre-filled syringe EU/1/18/1286/002 2 pre-filled syringes 
EU/1/18/1286/001 1 napolnjena injekcijska brizga EU/1/18/1286/002 2 napolnjeni injekcijski brizgi
Hyrimoz is used to treat psoriatic arthritis in adults. 
Zdravilo Hyrimoz se uporablja za zdravljenje psoriatičnega artritisa pri odraslih.
Polyarticular juvenile idiopathic arthritis from 2 years of age The recommended dose of Hyrimoz for patients with polyarticular juvenile idiopathic arthritis from 2 years of age is based on body weight (table 1). 
Priporočeni odmerek zdravila Hyrimoz pri bolnikih s poliartikularnim juvenilnim idiopatskim artritisom od 2. leta starosti, temelji na telesni masi (preglednica 1).
Glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs, or analgesics can be continued during treatment with Hyrimoz. 
salicilatov, nesteroidnih protivnetnih zdravil ali analgetikov.
Talk to your doctor or pharmacist before using Hyrimoz. 
Pred začetkom uporabe zdravila Hyrimoz se posvetujte z zdravnikom ali farmacevtom.
• In some patients the body may fail to produce enough of the blood cells that fight off infections or help you to stop bleeding. 
Zvišana telesna temperatura, podplutbe, krvavitve, bledica • Pri nekaterih bolnikih telo ne ustvari dovolj krvnih celic, ki premagujejo okužbo ali pomagajo pri ustavitvi krvavitve.
Hyrimoz dose for paediatric patients with plaque psoriasis Patient weight 
Odmerjanje zdravila Hyrimoz pri pediatričnih bolnikih s psoriazo v plakih
Each syringe contains 40 mg/0.8 ml of Hyrimoz. 
Ena injekcijska brizga vsebuje 40 mg/0,8 ml zdravila Hyrimoz.
You should record the date when your pre-filled syringe is first removed from the refrigerator, and the date after which it should be discarded. 
Zapisati si morate datum, ko je bila napolnjena injekcijska brizga vzeta iz hladilnika, in datum, po katerem jo je treba zavreči.
Hyrimoz contains sodium 
Zdravilo Hyrimoz vsebuje natrij
Hyrimoz is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies. 
Zdravilo Hyrimoz je indicirano za zdravljenje zmerno do hudo aktivne Crohnove bolezni pri pediatričnih bolnikih (od 6. leta starosti), ki se ne odzovejo zadovoljivo na konvencionalno zdravljenje, vključno s primarno prehransko terapijo in kortikosteroidom in/ali imunomodulatorjem,
Plaque psoriasis can also affect the nails, causing them to crumble, become thickened and lift away from the nail bed which can be painful. 
Luskavica v plakih lahko prizadene tudi nohte, ki postanejo krušljivi,
EU/1/18/1286/006 6 pre-filled pens (3 packs of 2) 
EU/1/18/1286/006 6 napolnjenih injekcijskih peresnikov (3 pakiranja po 2)
Your Hyrimoz single-use pre-filled syringe with needle guard and add-on finger flange 
Vaša napolnjena injekcijska brizga zdravila Hyrimoz z varovalnim pokrovčkom in držalom
The recommended Hyrimoz dose is 80 mg at week 0 followed by 40 mg every other week starting at week 1 via subcutaneous injection. 
Priporočeni odmerek zdravila Hyrimoz je 80 mg v 0. tednu, ki mu sledi 40 mg vsak drugi teden z začetkom v 1. tednu, v obliki subkutane injekcije.
Multipack cartons contain 6 (3 packs of 2) pre-filled syringes of Hyrimoz. 
Škatle za večkratno pakiranje vsebujejo 6 (3 pakiranja po 2) napolnjenih injekcijskih brizg zdravila Hyrimoz.
Hyrimoz 40 mg solution for injection in pre-filled syringe Hyrimoz 40 mg solution for injection in pre-filled pen 
Hyrimoz 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Hyrimoz 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku
All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of PUVA treatment should be examined for the presence of nonmelanoma skin cancer prior to and during treatment with Hyrimoz. 
Pred zdravljenjem z zdravilom Hyrimoz in med zdravljenjem z njim je treba za nemelanomskega kožnega raka pregledati vse bolnike, še zlasti pa bolnike z anamnezo intenzivne imunosupresivne terapije in bolnike s psoriazo, ki so kdaj prejemali PUVA.
EU/1/18/1286/004 1 pre-filled pen EU/1/18/1286/005 2 pre-filled pens 
EU/1/18/1286/004 1 napolnjen injekcijski peresnik EU/1/18/1286/005 2 napolnjena injekcijska peresnika
The recommended dose of Hyrimoz for patients with enthesitis-related arthritis from 6 years of age is based on body weight (table 2). 
Priporočeni odmerek zdravila Hyrimoz pri bolnikih z artritisom, povezanim z entezitisom, starih 6 let in več, temelji na telesni masi (preglednica 2).
Children and adolescents from 6 to 17 years of age weighing 40 kg or more 
Otroci in mladostniki, stari od 4 do 17 let, ki tehtajo 30 kg ali več
Opportunistic infections, including invasive fungal infections have been observed in patients receiving adalimumab. 
Pri bolnikih, ki so dobivali adalimumab, so opažali oportunistične okužbe, vključno z invazivnimi glivičnimi okužbami.
Room spinning sensation (vertigo) and vision disturbances may occur after taking Hyrimoz. 
Po dajanju zdravila Hyrimoz se lahko pojavita vrtoglavica (občutek vrtenja prostora) in poslabšanje vida.
Hyrimoz is used to treat ulcerative colitis in adults. 
Zdravilo Hyrimoz se uporablja za zdravljenje ulceroznega kolitisa pri odraslih.
In adolescent patients with inadequate response to Hyrimoz 40 mg every other week, an increase in dosage to 40 mg every week or 80 mg every other week may be considered. 
Pri mladostnikih z nezadostnim odzivom na zdravilo Hyrimoz 40 mg vsak drugi teden je možno razmisliti o povečanju odmerka na 40 mg vsak teden ali na 80 mg vsak drugi teden.